AI Article Synopsis

  • There’s currently no effective treatment for COVID-19, and vaccinations lose effectiveness against new variants over time, highlighting the need for affordable anti-SARS-CoV-2 medications.
  • ArtemiC, which combines natural ingredients like artemisinin and curcumin, was tested in a Phase II study to evaluate its safety and effectiveness on hospitalized symptomatic COVID-19 patients.
  • The study found that ArtemiC improved patient conditions significantly without adverse side effects, suggesting it may help prevent the worsening of COVID-19, especially in those with existing health issues.

Article Abstract

Despite intensive efforts, there is no effective remedy for COVID-19. Moreover, vaccination efficacy declines over time and may be compromised against new SARS-CoV-2 lineages. Therefore, there remains an unmet need for simple, accessible, low-cost and effective pharmacological anti-SARS-CoV-2 agents. ArtemiC is a medical product comprising artemisinin, curcumin, frankincense and vitamin C, all of which possess anti-inflammatory and anti-oxidant properties. The present Phase II placebo-controlled, double-blinded, multi-centred, prospective study evaluated the efficacy and safety of ArtemiC in patients with COVID-19. The study included 50 hospitalized symptomatic COVID-19 patients randomized (2:1) to receive ArtemiC or placebo oral spray, twice daily on Days 1 and 2, beside standard care. A physical examination was performed, and vital signs and blood tests were monitored daily until hospital discharge (or Day 15). A PCR assessment of SARS-CoV-2 carriage was performed at screening and on last visit. ArtemiC improved NEWS2 in 91% of patients and shortened durations of abnormal SpO levels, oxygen supplementation and fever. No treatment-related adverse events were reported. These findings suggest that ArtemiC curbed deterioration, possibly by limiting cytokine storm of COVID-19, thus bearing great promise for COVID-19 patients, particularly those with comorbidities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9170814PMC
http://dx.doi.org/10.1111/jcmm.17337DOI Listing

Publication Analysis

Top Keywords

artemic patients
8
patients covid-19
8
prospective study
8
covid-19 patients
8
artemic
6
covid-19
6
covid-19 phase
4
phase prospective
4
study despite
4
despite intensive
4

Similar Publications

Despite intensive efforts, there is no effective remedy for COVID-19. Moreover, vaccination efficacy declines over time and may be compromised against new SARS-CoV-2 lineages. Therefore, there remains an unmet need for simple, accessible, low-cost and effective pharmacological anti-SARS-CoV-2 agents.

View Article and Find Full Text PDF

Background: COVID-19 infection poses a serious risk to patients and - due to its contagious nature - to those healthcare workers (HCWs) treating them. If the mouth and nose of patients with infection are irrigated with antimicrobial solutions, this may help the patients by killing any coronavirus present at those sites. It may also reduce the risk of the active infection being passed to HCWs through droplet transmission or direct contact.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!